Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 20/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.74 |
| ▸ | HTR2B | P41595 | 1/20 | 0.74 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15942032 | 0.86 | GRM4 (1.00) | GRM4KCNH2HTR2BMTNR1A | |
| SCHEMBL7859091 | 0.84 | GRM4 (1.00) | GRM4KCNH2HTR2BMTNR1A | |
| SCHEMBL2710540 | 0.80 | GRM4 (0.77) | GRM4KCNH2HTR2BMTNR1A | |
| SCHEMBL28199101 | 0.79 | GRM4 (0.85) | GRM4KCNH2HTR2BMTNR1A | |
| SCHEMBL17125376 | 0.78 | GRM4 (0.67) | GRM4KCNH2HTR2BMTNR1A | |
| SCHEMBL355762 | 0.74 | GRM4 (0.65) | GRM4KCNH2HTR2BMTNR1A | |
| SCHEMBL31428975 | 0.74 | GRM4 (0.65) | GRM4KCNH2HTR2BMTNR1A | |
| SCHEMBL20061111 | 0.70 | CA12 (0.55) | — | |
| SCHEMBL5216629 | 0.69 | PDE10A (0.44) | GRM4 | |
| SCHEMBL5216817 | 0.69 | GRM4 (0.87) | GRM4KCNH2HTR2BMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | ELECTROPHORETICS LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | CSNK1G1, CSNK1A1, CSNK1D | GRM4 2827/4885KCNH2 2523/4885HTR2B 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.